AT Bancorp continued to hold its position in Chemed Corp. (NYSE:CHE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,000 shares of the company’s stock at the end of the second quarter. AT Bancorp’s holdings in Chemed Corp. were worth $409,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the company. Glen Harbor Capital Management LLC boosted its stake in shares of Chemed Corp. by 11.4% in the first quarter. Glen Harbor Capital Management LLC now owns 624 shares of the company’s stock worth $114,000 after buying an additional 64 shares during the last quarter. TrimTabs Asset Management LLC boosted its stake in shares of Chemed Corp. by 88.7% in the first quarter. TrimTabs Asset Management LLC now owns 732 shares of the company’s stock worth $134,000 after buying an additional 344 shares during the last quarter. Tyers Asset Management LLC boosted its stake in shares of Chemed Corp. by 11.4% in the first quarter. Tyers Asset Management LLC now owns 858 shares of the company’s stock worth $157,000 after buying an additional 88 shares during the last quarter. Flinton Capital Management LLC boosted its stake in Chemed Corp. by 11.4% in the first quarter. Flinton Capital Management LLC now owns 1,092 shares of the company’s stock worth $199,000 after buying an additional 112 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Chemed Corp. during the second quarter worth about $209,000. 97.78% of the stock is owned by institutional investors.
Shares of Chemed Corp. (NYSE CHE) opened at 187.59 on Friday. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 46.54 and a beta of 1.14. Chemed Corp. has a one year low of $130.05 and a one year high of $216.01. The company has a 50-day moving average of $199.37 and a 200 day moving average of $192.75.
Chemed Corp. (NYSE:CHE) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business had revenue of $415.06 million during the quarter, compared to analysts’ expectations of $407.56 million. During the same quarter in the previous year, the firm earned $1.80 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. Equities research analysts forecast that Chemed Corp. will post $8.20 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Monday, August 14th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Thursday, August 10th. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.26. Chemed Corp.’s payout ratio is currently 28.07%.
WARNING: “AT Bancorp Holds Stake in Chemed Corp. (NYSE:CHE)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/19/chemed-corp-nyseche-position-held-by-at-bancorp-updated.html.
CHE has been the topic of a number of research analyst reports. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. BidaskClub cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $209.00 target price on shares of Chemed Corp. in a research note on Monday, July 31st. Finally, Oppenheimer Holdings, Inc. lifted their target price on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Chemed Corp. presently has a consensus rating of “Hold” and a consensus price target of $218.33.
In related news, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction dated Friday, July 28th. The stock was sold at an average price of $201.16, for a total transaction of $3,017,400.00. Following the completion of the transaction, the insider now owns 173,801 shares of the company’s stock, valued at approximately $34,961,809.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George J. Walsh III acquired 1,000 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were acquired at an average cost of $204.56 per share, with a total value of $204,560.00. Following the transaction, the director now directly owns 7,908 shares in the company, valued at approximately $1,617,660.48. The disclosure for this purchase can be found here. 5.32% of the stock is currently owned by insiders.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.